Not a healthcare professional? Visit our Public site
For UK Healthcare Professionals
This site may contain promotional material
Report adverse event
User logged in
Trelegy▼ (fluticasone furoate/umeclidinium/vilanterol) prescribing information
Relvar▼ (fluticasone furoate/vilanterol) prescribing information
Anoro▼ (umeclidinium/vilanterol) prescribing information
Incruse▼ (umeclidinium bromide) prescribing information
Share this page
This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.
Explore our Ellipta portfolio
Our asthma products, clinical evidence and expert perspectives, as well as resources to help support you and your asthma patients.
Learn more about our COPD products, listen to GSK Global Medical Experts and hear about our key clinical studies in COPD.
Fewer patients make critical errors using Ellipta compared with other commonly used inhalers, after reading the patient information leaflet.
Demonstration device for healthcare professionals to show patients how to use the Ellipta device correctly.
IMPORTANT: The Ellipta demonstration device is intended for demonstrating only and not for patient use. Patients should not put the demonstration inhaler in their mouth.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
Anoro, Incruse, Relvar, Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies
N.M. Last updated: November 2017. UK/RESP/0203/17(1)
Get in touch
To discuss our products, supply, educational events or any other information
© 2009-2017 GSK group of companies. All rights reserved. GlaxoSmithKline UK Limited Registered in England and Wales No 4310159.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
M.C. Last updated: April 2017. UK/COM/0106/15(1).
This browser is not supported and will result in the website not being optimally presented. You are recommended to use an alternate browser such as Chrome, Opera or FireFox